Novorapid Innolet (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid Innolet, is a rapid‑acting insulin analog presented as a clear solution for subcutaneous use. It is used to control blood glucose levels in patients with diabetes mellitus, including both type 1 and type 2 disease, by providing a fast‑onset insulin effect after injection.

GNH USA supplies Novorapid Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Novorapid Innolet, a rapid‑acting insulin analog, is employed in the management of diabetes mellitus to achieve prompt post‑prandial glucose control.

- Type 1 diabetes mellitus: provides rapid insulin replacement to mimic physiological secretion after meals. - Type 2 diabetes mellitus: used as part of intensive insulin regimens to lower post‑prandial glucose excursions.

Novorapid Innolet may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycemia: low blood glucose levels, often presenting with sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in subcutaneous fat tissue. - Weight gain: modest increase in body weight due to improved glycemic control.

Serious or Rare Side Effects: - Severe hypoglycemia: prolonged or unconscious episodes requiring assistance. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Insulin antibody formation: may affect insulin efficacy.

When using Novorapid Innolet, clinicians and patients should observe several safety considerations to minimize risks.

- Dose adjustment: tailor insulin dose based on blood glucose monitoring and carbohydrate intake. - Renal impairment: monitor closely as reduced clearance may increase hypoglycemia risk. - Hepatic dysfunction: use with caution; altered glucose metabolism may affect insulin requirements. - Pregnancy and lactation: evaluate benefits versus risks; limited data are available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Novorapid Innolet can interact with other medicines, altering its glucose‑lowering effect or increasing adverse event potential.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms and prolong insulin action. - Corticosteroids: can cause significant hyperglycemia, necessitating insulin dose increase.

Moderate Interactions (Monitor Closely): - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect may raise hypoglycemia risk. - Alcohol: can potentiate insulin’s hypoglycemic action, especially with fasting. - Thyroid hormones: may increase insulin clearance, requiring dose adjustment.